[开放获取]    β受体阻滞剂治疗婴儿血管瘤中国专家共识

doi:10.35541/cjd.20200302

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (7): 493-500.doi: 10.35541/cjd.20200302

• 指南与共识 • 下一篇

[开放获取] β受体阻滞剂治疗婴儿血管瘤中国专家共识

中华医学会皮肤性病学分会儿童学组¹,中华医学会儿科学分会皮肤性病学组²,中国医师协会皮肤科医师分会儿童……³,中国康复医学会皮肤病康复专业委员会⁴,李丽⁵,马琳⁵,王华⁶,汤建萍⁷,陈谨萍⁸,付桂莉⁹,甘立强¹⁰,高宇¹¹,郭艳萍¹²,¹²,李萍¹³,李钦峰¹⁴,李云玲¹⁵,钱华¹⁶,钱秋芳¹⁷,舒虹¹⁸,王榴慧¹⁹,卫风蕾²⁰,徐子刚²¹,陈萍²²,迪力拜尔·热夏提²³,樊平申²⁴,何洛芸²⁵,姬爱华²⁶,宋俐²⁷,王永平²⁸

1. 中华医学会皮肤性病学分会儿童学组
2. 中华医学会儿科学分会皮肤性病学组
3. 中国医师协会皮肤科医师分会儿童皮肤病专业委员会
4. 中国康复医学会皮肤病康复专业委员会
5. 国家儿童医学中心首都医科大学附属北京儿童医院皮肤科 100045
6. 重庆医科大学附属儿童医院
7. 湖南省儿童医院
8. 广州市儿童医院皮肤科
9. 华中科技大学同济医学院附属武汉儿童医院皮肤科
10. 重庆医科大学附属儿童医院皮肤科
11. 温州医学院附属第二医院皮肤科
12. 黑龙江省哈尔滨市儿童医院皮肤科
13. 深圳市儿童医院皮肤科
14. 天津市儿童医院皮肤科
15. 浙江大学医学院附属儿童医院
16. 苏州大学附属儿童医院
17. 上海市儿童医院
18. 昆明市儿童医院皮肤科
19. 复旦大学附属儿科医院
20. 大连市儿童医院
21. 首都医科大学附属北京儿童医院
22. 徐州医科大学附属徐州儿童医院
23. 乌鲁木齐市第一人民医院（儿童医院）
24. 第四军医大学
25. 广西壮族自治区妇幼保健院
26. 山东大学齐鲁儿童医院
27. 郑州大学附属儿童医院河南省儿童医院郑州儿童医院
28. 长春市儿童医院

收稿日期:2020-03-27 修回日期:2020-05-07 发布日期:2020-07-06
通讯作者: 马琳 E-mail:bch_maleen@aliyun.com

Chinese expert consensus on β-blockers for the treatment of infantile hemangioma

Received:2020-03-27 Revised:2020-05-07 Published:2020-07-06
Contact: Ma Lin E-mail:bch_maleen@aliyun.com

摘要/Abstract

摘要： 【摘要】 β受体阻滞剂是目前治疗婴儿血管瘤的一线药物，主要包括口服普萘洛尔和外用噻吗洛尔/卡替洛尔滴眼液。β受体阻滞剂药物选择及给药方式主要根据患儿年龄、瘤体部位、分型、分类及大小等因素综合决定。本共识对口服普萘洛尔的适应证及禁忌证、治疗起始时间及剂量、疗程与停药指征、用药期间注意事项和不良反应的监测及处理和特殊人群治疗剂量、疗程以及外用β受体阻滞剂适应证、应用具体方法等进行总结，希望为皮肤科及相关专业医生规范应用β受体阻滞剂治疗婴儿血管瘤提供参考依据。

关键词: 血管瘤, 婴儿, 肾上腺素能β受体拮抗剂, 普萘洛尔, 噻吗洛尔, 卡替洛尔, 专家共识

Abstract: 【Abstract】 Currently, β-blockers are the first-line drugs for the treatment of infantile hemangioma, mainly including oral propranolol and topical timolol/carteolol eye drops. The selection and administration of β-blockers are mainly determined by factors such as children′s age, as well as tumor site, type, classification and size. This consensus summarizes indications and contraindications of oral propranolol, timing for initial therapy, start dose, start dose, course of treatment, indications for withdrawal, cautions during treatment, monitoring and management of adverse reactions, as well as therapeutic dose and course for special populations. The indications and specific administration methods of topical β-blockers are also described. It is hoped that this consensus provides a reference for dermatologists and relevant professional clinicians in proper application of β-blockers in the treatment of infantile hemangioma.

Key words: Hemangioma, Infant, Adrenergic beta-antagonists, Propranolol, Timolol, Carteolol, Expert consensus

中华医学会皮肤性病学分会儿童学组中华医学会儿科学分会皮肤性病学组中国医师协会皮肤科医师分会儿童…… 中国康复医学会皮肤病康复专业委员会李丽马琳王华汤建萍陈谨萍付桂莉甘立强高宇郭艳萍李萍李钦峰李云玲钱华钱秋芳舒虹王榴慧卫风蕾徐子刚陈萍迪力拜尔·热夏提樊平申何洛芸姬爱华宋俐王永平. [开放获取] β受体阻滞剂治疗婴儿血管瘤中国专家共识[J]. 中华皮肤科杂志, 2020,53(7):493-500. doi:10.35541/cjd.20200302

参考文献 43

［1］	Bauland CG, Lüning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions［J］. Plast Reconstr Surg, 2011,127（4）:1643⁃1648. doi: 10.1097/PRS.0b013 e318208d2ac.
［2］	Léauté⁃Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy［J］. N Engl J Med, 2008,358（24）:2649⁃2651. doi: 10.1056/NEJMc0708819.
［3］	Babiak⁃Choroszczak L, Giżewska⁃Kacprzak K, Dawid G, et al. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas［J］. Adv Clin Exp Med, 2019,28（3）:375⁃384. doi: 10.17219/acem/94136.
［4］	Léauté⁃Labrèze C, Hoeger P, Mazereeuw⁃Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma［J］. N Engl J Med, 2015,372（8）:735⁃746. doi: 10. 1056/NEJMoa1404710.
［5］	Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review［J］. Pediatr Dermatol, 2013,30（2）:182⁃191. doi: 10.1111/pde.12089.
［6］	Li L, Wei L, Xu ZG, et al. No increased risks associated with propranolol treatment for infantile hemangioma in preterm infants were identified at 3 years of age［J］. Am J Clin Dermatol, 2019,20（2）:289⁃293. doi: 10.1007/s40257⁃018⁃00419⁃1.
［7］	López⁃Gutiérrez JC. Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single⁃center experience from La Paz Hospital, Madrid［J］. Eur J Pediatr, 2019,178（1）:1⁃6. doi: 10.1007/s00431⁃018⁃3290⁃z.
［8］	Smithson SL, Rademaker M, Adams S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol［J］. Australas J Dermatol, 2017,58（2）:155⁃159. doi: 10.1111/ajd.12600.
［9］	Solman L, Glover M, Beattie PE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines［J］. Br J Dermatol, 2018,179（3）:582⁃589. doi: 10.1111/bjd.16779.
［10］	Baselga Torres E, Bernabéu Wittel J, van Esso Arbolave DL, et al. Spanish consensus on infantile haemangioma［J］. An Pediatr （Barc）, 2016,85（5）:256⁃265. doi: 10.1016/j.anpedi.2015.10.004.
［11］	Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference［J］. Pediatrics, 2013,131（1）:128⁃140. doi: 10.1542/peds.2012⁃1691.
［12］	Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group［J］. Eur J Pediatr, 2015,174（7）:855⁃865. doi: 10.1007/s00431⁃015⁃2570⁃0.
［13］	中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南（2019版）［J］. 组织工程与重建外科杂志, 2019,15（5）:277⁃317. doi: 10.3969/j.issn.1673⁃0364. 2019.05.001.
［14］	Lee D, Boscolo E, Durham JT, et al. Propranolol targets the contractility of infantile haemangioma⁃derived pericytes［J］. Br J Dermatol, 2014,171（5）:1129⁃1137. doi: 10.1111/bjd.13048.
［15］	Pan WK, Li P, Guo ZT, et al. Propranolol induces regression of hemangioma cells via the down⁃regulation of the PI3K/Akt/eNOS/VEGF pathway［J］. Pediatr Blood Cancer, 2015,62（8）:1414⁃1420. doi: 10.1002/pbc.25453.
［16］	Yuan WL, Jin ZL, Wei JJ, et al. Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients［J］. Br J Oral Maxillofac Surg, 2013,51（7）:656⁃661. doi: 10.1016/j.bjoms. 2012.12.003.
［17］	Li D, Li P, Guo Z, et al. Downregulation of miR⁃382 by propranolol inhibits the progression of infantile hemangioma via the PTEN⁃mediated AKT/mTOR pathway［J］. Int J Mol Med, 2017,39（3）:757⁃763. doi: 10.3892/ijmm.2017.2863.
［18］	Lamy S, Lachambre MP, Lord⁃Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells［J］. Vascul Pharmacol, 2010,53（5⁃6）:200⁃208. doi: 10.1016/j.vph.2010.08. 002.
［19］	Ma X, Zhao T, Ouyang T, et al. Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells［J］. Int J Clin Exp Pathol, 2014,7（7）:3809⁃3817.
［20］	Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas［J］. Pediatrics, 2019,143（1）:e20183475. doi: 10.1542/peds.2018⁃3475.
［21］	Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management［J］. Pediatrics, 2008,122（2）:360⁃367. doi: 10. 1542/peds.2007⁃2767.
［22］	Yu Z, Cai R, Chang L, et al. Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: a long⁃term follow⁃up study［J］. J Dermatol, 2019,46（5）:376⁃382. doi: 10.1111/1346⁃8138.14853.
［23］	Onnis G, Dreyfus I, Mazereeuw⁃Hautier J. Factors associated with delayed referral for infantile hemangioma necessitating propranolol［J］. J Eur Acad Dermatol Venereol, 2018,32（9）:1584⁃1588. doi: 10.1111/jdv.14842.
［24］	Li L, Ma L. Use of propranolol on a nasal hemangioma in an extremely low birthweight premature infant［J］. J Dermatol, 2015,42（11）:1101⁃1102. doi: 10.1111/1346⁃8138.13029.
［25］	Brandling⁃Bennett HA, Metry DW, Baselga E, et al. Infantile hemangiomas with unusually prolonged growth phase: a case series［J］. Arch Dermatol, 2008,144（12）:1632⁃1637. doi: 10. 1001/archderm.144.12.1632.
［26］	Lamy S, Lachambre MP, Lord⁃Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells［J］. Vascul Pharmacol, 2010,53（5⁃6）:200⁃208. doi: 10.1016/j.vph.2010.08. 002.
［27］	Vivas⁃Colmenares GV, Bernabeu⁃Wittel J, Alonso⁃Arroyo V, et al. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase［J］. Pediatr Dermatol, 2015,32（3）:348⁃352. doi: 10.1111/pde.12520.
［28］	Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study［J］. Pediatr Dermatol, 2011,28（2）:94⁃98. doi: 10.1111/j.1525⁃1470.2010.01379.x.
［29］	Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites［J］. N Engl J Med, 1989,320（9）:565⁃570. doi: 10.1056/NEJM198903023200905.
［30］	Zhou HH, Shay SD, Wood AJ. Contribution of differences in plasma binding of propranolol to ethnic differences in sensitivity. Comparison between Chinese and Caucasians［J］. Chin Med J （Engl）, 1993,106（12）:898⁃902.
［31］	Fogel I, Ollech A, Zvulunov A, et al. Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day⁃care hospitalization setting［J］. J Eur Acad Dermatol Venereol, 2018,32（11）:2004⁃2009. doi: 10.1111/jdv. 14955.
［32］	于鲁, 李丽, 马琳. 口服普萘洛尔治疗婴儿血管瘤的近期和远期安全性［J］. 中华皮肤科杂志, 2019,52（8）:586⁃589. doi: 10.3760/cma.j.issn.0412⁃4030.2019.08.019.
［33］	李丽, 徐子刚, 孙玉娟, 等. 普萘洛尔治疗婴儿血管瘤复发因素分析［J］. 中华皮肤科杂志, 2017,50（2）:77⁃80. doi: 10.3760/cma.j.issn.0412⁃4030.2017.02.001.
［34］	Bagazgoitia L, Hernández⁃Martín A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol［J］. Pediatr Dermatol, 2011,28（6）:658⁃662. doi: 10.1111/j.1525⁃1470.2011. 01644.x.
［35］	Baselga E, Dembowska⁃Baginska B, Przewratil P, et al. Efficacy of propranolol between 6 and 12 months of age in high⁃risk infantile hemangioma［J］. Pediatrics, 2018,142（3）:e20173866. doi: 10.1542/peds.2017⁃3866.
［36］	O′Brien KF, Shah SD, Pope E, et al. Late growth of infantile hemangiomas in children >3 years of age: a retrospective study［J］. J Am Acad Dermatol, 2019,80（2）:493⁃499. doi: 10.1016/j.jaad.2018.07.061.
［37］	Rangno RE, Nattel S, Lutterodt A. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule［J］. Am J Cardiol, 1982,49（4）:828⁃833. doi: 10.1016/0002⁃9149（82）91965⁃8.
［38］	Love JN, Sikka N. Are 1⁃2 tablets dangerous? Beta⁃blocker exposure in toddlers［J］. J Emerg Med, 2004,26（3）:309⁃314. doi: 10.1016/j.jemermed.2003.11.015.
［39］	Gonski K, Wargon O. Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children′s Hospital［J］. Australas J Dermatol, 2014,55（3）:209⁃211. doi: 10.1111/ajd. 12156.
［40］	Moyakine AV, Hermans DJ, Fuijkschot J, et al. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development［J］. J Am Acad Dermatol, 2015,73（2）:341⁃342. doi: 10.1016/j.jaad.2015.04.053.
［41］	Moyakine AV, Kerstjens JM, Spillekom⁃van Koulil S, et al. Propranolol treatment of infantile hemangioma （IH） is not associated with developmental risk or growth impairment at age 4 years［J］. J Am Acad Dermatol, 2016,75（1）:59⁃63.e1. doi: 10.1016/j.jaad.2016.02.1218.
［42］	刘笑宇, 李丽, 尉莉, 等. 2%卡替洛尔溶液局部治疗婴儿血管瘤的疗效及安全性研究［J］. 临床皮肤科杂志, 2017,46（01）:68⁃70.
［43］	李丽, 王华, 王榴慧, 等. 多磺酸黏多糖减少中、低风险婴儿血管瘤治疗后发生湿疹及皮肤萎缩的多中心研究［J］. 中华皮肤科杂志, 2019,52（10）:779⁃784. doi: 10.35541/cjd.20190196.

[1]	中国医师协会皮肤科医师分会. [开放获取] 保湿润肤类产品应用指导专家共识（2023版）[J]. 中华皮肤科杂志, 2023, 56(8): 711-717.
[2]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539.
[3]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 479-488.
[4]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 489-495.
[5]	王敏何萍秀程丽芳洪克春艾勇. 头皮脑（脊）膜错构瘤1例[J]. 中华皮肤科杂志, 2023, 56(5): 449-450.
[6]	《蕈样肉芽肿治疗中国专家共识》编写专家组. [开放获取] 蕈样肉芽肿治疗中国专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 402-409.
[7]	闫娜陈婷耿松梅李政霄刘燕马迎新谭宣丰. 皮下非对称减张联合真皮埋没成角褥式缝合在婴幼儿面部良性色素性皮损手术治疗中的应用[J]. 中华皮肤科杂志, 2023, 0(4): 20210659-e20210659.
[8]	杨开颖龚雪邱桐周江元兰钰茹吉毅. 糖酵解关键酶PFKFB3对婴幼儿血管瘤内皮细胞增殖、迁移及凋亡的影响[J]. 中华皮肤科杂志, 2023, 56(4): 320-324.
[9]	中华医学会皮肤性病学分会中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病学分会中国医药教育协会皮肤病专业委员会. 老年带状疱疹诊疗专家共识[J]. 中华皮肤科杂志, 2023, 56(2): 97-104.
[10]	谢德琼杨开颖杨旸陈思源吉毅. 长链非编码RNA在婴幼儿血管瘤中的研究进展[J]. 中华皮肤科杂志, 2023, 56(12): 1173-1176.
[11]	中国研究型医院学会皮肤科学专业委员会中国医师协会皮肤科医师分会. [开放获取] 慢性光化性皮炎诊疗专家共识（2023版）[J]. 中华皮肤科杂志, 2023, 56(12): 1096-1106.
[12]	上海市医学会皮肤性病学分会上海市医学会肿瘤靶分子专科分会. [开放获取] 抗肿瘤药物相关皮肤不良反应管理专家共识[J]. 中华皮肤科杂志, 2023, 56(10): 907-919.
[13]	中国医师协会皮肤科医师分会中国研究型医院学会皮肤科学专业委员会. 中国卡波西肉瘤诊疗专家共识（2023版）[J]. 中华皮肤科杂志, 2023, 56(10): 899-906.
[14]	邱桐杨开颖龚雪周江元张学鹏兰钰茹陈思源吉毅. 婴幼儿血管瘤相关危险因素的多中心病例对照研究[J]. 中华皮肤科杂志, 2022, 55(9): 772-777.
[15]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中华医学会皮肤性病学分会儿童学组. 【开放获取】特应性皮炎湿包疗法临床应用专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 289-294.

[开放获取] β受体阻滞剂治疗婴儿血管瘤中国专家共识

Chinese expert consensus on β-blockers for the treatment of infantile hemangioma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

Metrics

本文评价

推荐阅读 10